QUICK LINKS
MAIN MENU
CONNECT WITH US

Button

Clinical Trial Details

Title
COBRA 2015-01 Randomized Trial of Cobra PzF Stenting to Reduce Duration of Triple Therapy (COBRA-REDUCE)
Study Description

The purpose of the study is to collect information about the safety and effectiveness of the COBRA PzF Coronary Stent System in the treatment of de novo lesions in native coronary arteries with a shortened duration of dual antiplatelet therapy

Investigational Treatment: The COBRA PzF™ Coronary Stent System (CeloNova BioSciences, San Antonio, Texas) is a balloon-expandable bare metal coronary stent (a tube like to keep your artery open to allow blood flow to your heart) coated with a thin layer of novel Polyzene-F polymer with 14 days of dual antiplatelet therapy (blood thinner) after stenting. Control Treatment: The control treatment is a commercially available drug eluting stent (Xience/Promus or Resolute) with 6 months of dual antiplatelet therapy after stenting

Investigators

Principal Investigator
Dominick J. Angiolillo, M.D., Ph.D., FACC
Medicine

Sub Investigator
Theodore A. Bass, M.D.
Medicine

Sub Investigator
Daniel Soffer, M.D.
Medicine

Sub Investigator
Siva Suryadevara, M.B.B.S. (M.D.)
Medicine

Sub Investigator
Martin "M" Zenni, M.D.
Medicine

Resources

News & Announcements

Upcoming Events

Apr 14